JP2010507666A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010507666A5 JP2010507666A5 JP2009534630A JP2009534630A JP2010507666A5 JP 2010507666 A5 JP2010507666 A5 JP 2010507666A5 JP 2009534630 A JP2009534630 A JP 2009534630A JP 2009534630 A JP2009534630 A JP 2009534630A JP 2010507666 A5 JP2010507666 A5 JP 2010507666A5
- Authority
- JP
- Japan
- Prior art keywords
- modulator
- fragment
- inhibit
- related disorder
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100034356 Casein kinase I isoform alpha-like Human genes 0.000 claims 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 238000000034 method Methods 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 101150070959 CK1 gene Proteins 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 150000003839 salts Chemical group 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 238000010171 animal model Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 230000007082 Aβ accumulation Effects 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 108091008103 RNA aptamers Proteins 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- QPCBNXNDVYOBIP-WHFBIAKZSA-N hymenialdisine Chemical compound NC1=NC(=O)C([C@@H]2[C@@H]3C=C(Br)N=C3C(=O)NCC2)=N1 QPCBNXNDVYOBIP-WHFBIAKZSA-N 0.000 claims 1
- ATBAETXFFCOZOY-UHFFFAOYSA-N hymenialdisine Natural products N1C(N)=NC(=O)C1=C1C(C=C(Br)N2)=C2C(=O)NCC1 ATBAETXFFCOZOY-UHFFFAOYSA-N 0.000 claims 1
- 229930188764 meridianine Natural products 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 230000004960 subcellular localization Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85433306P | 2006-10-25 | 2006-10-25 | |
| US60/854,333 | 2006-10-25 | ||
| PCT/US2007/022519 WO2008066626A2 (en) | 2006-10-25 | 2007-10-24 | METHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014076376A Division JP2014193865A (ja) | 2006-10-25 | 2014-04-02 | Ａβ関連障害の処置のための方法およびその組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010507666A JP2010507666A (ja) | 2010-03-11 |
| JP2010507666A5 true JP2010507666A5 (https=) | 2010-12-09 |
| JP5518479B2 JP5518479B2 (ja) | 2014-06-11 |
Family
ID=39468422
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009534630A Expired - Fee Related JP5518479B2 (ja) | 2006-10-25 | 2007-10-24 | Ａβ関連障害の処置のための方法およびその組成物 |
| JP2014076376A Pending JP2014193865A (ja) | 2006-10-25 | 2014-04-02 | Ａβ関連障害の処置のための方法およびその組成物 |
| JP2016124720A Pending JP2017014197A (ja) | 2006-10-25 | 2016-06-23 | Ａβ関連障害の処置のための方法およびその組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014076376A Pending JP2014193865A (ja) | 2006-10-25 | 2014-04-02 | Ａβ関連障害の処置のための方法およびその組成物 |
| JP2016124720A Pending JP2017014197A (ja) | 2006-10-25 | 2016-06-23 | Ａβ関連障害の処置のための方法およびその組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9532980B2 (https=) |
| EP (1) | EP2077838B1 (https=) |
| JP (3) | JP5518479B2 (https=) |
| ES (1) | ES2425179T3 (https=) |
| WO (1) | WO2008066626A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009146301A1 (en) | 2008-05-27 | 2009-12-03 | Yale University | TARGETING TGF-β AS A THERAPY FOR ALZHEIMER'S DISEASE |
| JP2011526925A (ja) * | 2008-07-01 | 2011-10-20 | ザカロン ファーマシューティカルズ，インク． | ヘパラン硫酸阻害剤 |
| US9468649B2 (en) | 2008-12-05 | 2016-10-18 | The Regents Of The University Of California | Methods of treating epilepsy with transforming growth factor beta inhibitors |
| US9414409B2 (en) | 2012-02-06 | 2016-08-09 | Samsung Electronics Co., Ltd. | Method and apparatus for transmitting/receiving data on multiple carriers in mobile communication system |
| JPWO2014007367A1 (ja) * | 2012-07-05 | 2016-06-02 | 国立大学法人 東京大学 | 同一試料中の２種の物質を検出又は測定する方法 |
| ES2728932T3 (es) | 2014-01-09 | 2019-10-29 | Intra Cellular Therapies Inc | Compuestos orgánicos |
| WO2018133835A1 (en) * | 2017-01-20 | 2018-07-26 | National Institute Of Biological Sciences, Beijing | Nucleoside analogue regulating mammalian circadian rhythm |
| JP7506473B2 (ja) * | 2019-12-20 | 2024-06-26 | ポッカサッポロフード＆ビバレッジ株式会社 | アミロイドβ蓄積抑制剤 |
| CN113234664B (zh) * | 2021-05-11 | 2024-05-10 | 澳门大学 | 一种胰腺祖细胞的制备方法及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5789650A (en) * | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) * | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6060296A (en) * | 1991-07-03 | 2000-05-09 | The Salk Institute For Biological Studies | Protein kinases |
| US5157378A (en) * | 1991-08-06 | 1992-10-20 | North-South Corporation | Integrated firefighter safety monitoring and alarm system |
| US5932448A (en) * | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US5545580A (en) * | 1995-09-19 | 1996-08-13 | United Microelectronics Corporation | Multi-state read-only memory using multiple polysilicon selective depositions |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6288089B1 (en) * | 1998-12-21 | 2001-09-11 | Michael Zawada | Use of kinase inhibitors for treating neurodegenerative diseases |
| DE60001229T2 (de) * | 1999-04-09 | 2003-10-30 | Smithkline Beecham Corp., Philadelphia | Triarylimidazole |
| ATE322016T1 (de) * | 1999-06-08 | 2006-04-15 | Aventis Pharma Inc | Screeningsverfahren zur änderung zirkadiane- rhythmus-eiweisse |
| ES2213996T3 (es) * | 1999-12-08 | 2004-09-01 | Centre National De La Recherche Scientifique (Cnrs) | Uso de himenialdisina o sus derivados en la fabricacion de medicamentos. |
| US6448057B1 (en) * | 2001-03-22 | 2002-09-10 | Applera Corporation | Isolated human casein kinase proteins, nucleic acid molecules encoding human casein kinase proteins, and uses thereof |
| AU2002316279B2 (en) | 2001-06-18 | 2007-08-23 | The Rockefeller University | Regulation of neuronal function through metabotropic glutamate receptor signaling pathways |
| EP1423103A4 (en) | 2001-08-10 | 2008-03-19 | Univ Rockefeller | COMPOSITIONS AND METHOD FOR MODULATING DARPP-32 PHOSPHORYLATION |
| US7008666B2 (en) * | 2001-11-26 | 2006-03-07 | Hormos Nutraceutical Oy Ltd. | Method of inhibiting overactivity of phagocytes or lymphocytes in an individual |
| GB0314943D0 (en) * | 2003-06-25 | 2003-07-30 | Proteome Sciences Plc | Screening methods |
| WO2005105987A1 (en) * | 2004-04-28 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with casein kinase 1, delta, isoform 2 (csnk1d iso 2) |
-
2007
- 2007-10-24 ES ES07870808T patent/ES2425179T3/es active Active
- 2007-10-24 US US12/447,080 patent/US9532980B2/en active Active
- 2007-10-24 JP JP2009534630A patent/JP5518479B2/ja not_active Expired - Fee Related
- 2007-10-24 WO PCT/US2007/022519 patent/WO2008066626A2/en not_active Ceased
- 2007-10-24 EP EP07870808A patent/EP2077838B1/en not_active Not-in-force
-
2014
- 2014-04-02 JP JP2014076376A patent/JP2014193865A/ja active Pending
-
2016
- 2016-06-23 JP JP2016124720A patent/JP2017014197A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010507666A5 (https=) | ||
| Fang et al. | Endothelial dysfunction in neurodegenerative diseases | |
| Ocasio et al. | scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy | |
| Vogg et al. | An evolutionarily-conserved Wnt3/β-catenin/Sp5 feedback loop restricts head organizer activity in Hydra | |
| Li et al. | An age-related sprouting transcriptome provides molecular control of axonal sprouting after stroke | |
| Ross et al. | Huntington's disease: from molecular pathogenesis to clinical treatment | |
| Madabhushi | The roles of DNA topoisomerase IIβ in transcription | |
| Lino Cardenas et al. | An HDAC9-MALAT1-BRG1 complex mediates smooth muscle dysfunction in thoracic aortic aneurysm | |
| Armstrong et al. | Cancer-associated muscle wasting—candidate mechanisms and molecular pathways | |
| Geister et al. | Advances in skeletal dysplasia genetics | |
| Rust et al. | Learning, AMPA receptor mobility and synaptic plasticity depend on n‐cofilin‐mediated actin dynamics | |
| Ochi et al. | Thirty years’ history since the discovery of Pax6: from central nervous system development to neurodevelopmental disorders | |
| Zou et al. | Reduction of mNAT1/hNAT2 contributes to cerebral endothelial necroptosis and Aβ accumulation in Alzheimer’s disease | |
| Wang et al. | The effects of apoptosis vulnerability markers on the myocardium in depression after myocardial infarction | |
| Sánchez et al. | Role of connexins 30, 36, and 43 in brain tumors, neurodegenerative diseases, and neuroprotection | |
| Zhu et al. | SNAP23 regulates endothelial exocytosis of von Willebrand factor | |
| Bros-Facer et al. | Treatment with an antibody directed against Nogo-A delays disease progression in the SOD1G93A mouse model of Amyotrophic lateral sclerosis | |
| Stone et al. | Genomics of human fibrotic diseases: disordered wound healing response | |
| Delangre et al. | S100 proteins in fatty liver disease and hepatocellular carcinoma | |
| CN110791560A (zh) | 一种用于阿尔茨海默病诊断和/或治疗的miRNA标志物 | |
| Shi et al. | Comparative insight into microglia/macrophages-associated pathways in glioblastoma and Alzheimer’s disease | |
| Chen et al. | CircFam190a: a critical positive regulator of osteoclast differentiation via enhancement of the AKT1/HSP90β complex | |
| Wirth et al. | Spinal muscular atrophy and therapeutic prospects | |
| O'Dea et al. | Are we there yet? Exploring astrocyte heterogeneity one cell at a time | |
| Doan et al. | Targeting orphan G protein-coupled receptor 17 with T0 ligand impairs glioblastoma growth |